Highest-materiality recent filing
Stockholders approved amendment to 2014 Equity Incentive Plan, increasing authorized shares by 6.5 million.
Kura Oncology Q1 2026: $5.8M KOMZIFTI net revenue in first full commercial quarter; cash $580.8M
Net product revenue $5.8M from KOMZIFTI in first full commercial quarter; 85 new patient starts, 157 total prescriptions.
Kura Oncology Q4 2025 net loss $81M; KOMZIFTI launch revenue $2.1M in first 5 weeks
Net loss of $81.0M in Q4 2025 vs $19.2M a year ago; full-year net loss $219.4M.
Kura Oncology reports $2.1M KOMZIFTI net revenue in first 5 weeks post-launch; cash at $667M
$2.1M KOMZIFTI net product revenue from Nov 21 to Dec 31, 2025 (first commercial sales).
First commercial sale of KOMZIFTI (ziftomenib) completed on December 2, 2025.
Kura Oncology announces FDA full approval of KOMZIFTI for NPM1-mutated AML
FDA granted full approval of KOMZIFTI (ziftomenib) on November 13, 2025 for R/R NPM1-mutated AML patients with no satisfactory alternative.
Kura Oncology Q3 net loss $74.1M; progress on ziftomenib Phase 3 trials
Net loss of $74.1M in Q3 2025 vs $54.4M in Q3 2024; R&D spend rose to $67.9M.
$30M milestone payment triggered by first patient dosed in KOMET-017 Phase 3 registrational trials.
Kura Oncology Q2 net loss widens to $66.1M; FDA sets Nov 30 PDUFA for ziftomenib NDA
Net loss $66.1M in Q2 2025 vs $50.8M in Q2 2024; collaboration revenue $15.3M from Kyowa Kirin.
Kura Oncology enters co-promotion agreement with Kyowa Kirin for ziftomenib in AML
Co-promotion and medical affairs agreement with Kyowa Kirin US for ziftomenib, a menin inhibitor for AML, dated June 27, 2025.
Kura Oncology reports high remission rates with ziftomenib in newly diagnosed AML trial
92% CRc (93% NPM1-m, 89% KMT2A-r) among 71 evaluable patients in KOMET-007 trial.
Kura Oncology's NDA for ziftomenib accepted with Priority Review; Phase 2 shows 23% CR/CRh rate
FDA accepted NDA for ziftomenib in R/R NPM1-m AML; Priority Review set; PDUFA date Nov 30, 2025.
Kura Oncology Q1 net loss $57.4M; NDA submitted for ziftomenib, $45M milestone earned
NDA for ziftomenib in R/R NPM1-mutant AML submitted March 31, 2025; FDA review period expected Q2 2025.
Kura Oncology reports Q4 net loss $19.2M; KOMET-001 trial hits primary endpoint; NDA plan Q2 2025
Q4 collaboration revenue $53.9M (from Kyowa Kirin), R&D $52.3M, net loss $19.2M vs $42.8M YoY.
Kura Oncology reports positive Phase 2 KOMET-001 trial of ziftomenib in R/R NPM1-m AML
KOMET-001 achieved primary endpoint CR+CRh with statistical significance; benefit-risk profile encouraging.
Kura Oncology CMO Stephen Dale resigns; Mollie Leoni named CMO, Francis Burrows CSO
Stephen Dale, M.D. resigned as CMO effective Jan 2, 2025 due to personal health challenges.
Upfront payment of $330M to Kura; near-term milestones up to $420M including launch of monotherapy R/R setting.
Kura Oncology Q3 net loss $54.4M; cash $455.3M; ziftomenib data expected early 2025
Net loss $54.4M in Q3 2024 vs $38.6M in Q3 2023; R&D expenses $41.7M.
Kura Oncology Q2 net loss $50.8M; cash $491.5M; ziftomenib pivotal data expected early 2025
Net loss $50.8M in Q2 2024 vs $37.2M in Q2 2023; R&D expenses $39.7M vs $28.2M.
Kura Oncology Q1 net loss $49.5M, cash $527M; ziftomenib gets BTD for NPM1-mutant AML
Net loss of $49.5M in Q1 2024 vs $34.1M in Q1 2023; cash $527M provides runway into 2027.
Kura Oncology Q4 net loss $42.8M; ziftomenib KOMET-001 enrollment on track for mid-2024
Net loss for Q4 2023 was $42.8M vs $33.1M in Q4 2022; full year loss $152.6M vs $135.8M.
Kura Oncology reports $424M cash; ziftomenib combo achieves 100% CR in newly diagnosed AML
Preliminary unaudited cash $424M as of Dec 31, 2023; net proceeds from private placement $146M.
Kura Oncology raises $150M via oversubscribed private placement at 29% premium
$150M gross proceeds from sale of 1.38M shares and 7.32M pre-funded warrants at $17.25/share.
Kura Oncology Q3 net loss $38.6M; cash $452.6M; ziftomenib trial enrollment on track for mid-2024
Net loss $38.6M vs $35.5M YoY; R&D $29.3M; cash $452.6M provides runway to mid-2026.
Kura Oncology Q2 net loss $37.2M; ziftomenib registration trial enrollment beats projections
Q2 2023 net loss $37.2M vs $34.8M in Q2 2022; R&D expenses $28.2M (up from $24.3M).
Kura Oncology prices $100M public offering of common stock and pre-funded warrants
Offering of 5,660,871 common shares at $11.50 and 3,034,782 pre-funded warrants at $11.4999 per warrant.
Kura Oncology reports 35% CR rate with ziftomenib in NPM1-mutant AML at EHA 2023
7 of 20 NPM1-mutant AML patients at 600 mg RP2D achieved complete remission (CR) with full count recovery.
Stockholders approve amendment increasing share reserve by 4.05M shares
At May 31 annual meeting, stockholders approved Amended 2014 Plan increasing authorized shares by 4,050,000.
Kura Oncology Q1 net loss $34.1M; ziftomenib enrollment outperforming projections
Net loss $34.1M vs $32.5M YoY; R&D expense $25.2M; cash $405.9M provides runway into Q4 2025.
Kura Oncology reports Phase 1 data for ziftomenib: 30% CR, 35% CRc in R/R NPM1-m AML at RP2D
In 20 NPM1-m R/R AML patients at 600mg RP2D: CR rate 30%, composite CR (CRc) 35%, ORR 40%.
Kura Oncology reports Q4 2022 net loss $33.1M; ziftomenib shows 30% CR rate in NPM1-mutant AML
Net loss Q4 2022 $33.1M, full year $135.8M; cash $438M provides runway into Q4 2025.
Kirsten Flowers resigns as Chief Commercial Officer effective Jan 27, 2023.
Phase 1b trial at 600 mg showed 30% CR (6/20) in NPM1-mutant AML vs 17% at 200 mg; median duration of response not reached.
Kura Oncology Q3 net loss $35.5M; $150M financing; ziftomenib data at ASH
Q3 net loss $35.5M vs $33.4M YoY; R&D expense $25.0M, G&A $11.6M.
Kura Oncology secures $25M equity from BMS and up to $125M debt from Hercules; runway into 2026
Bristol Myers Squibb invests $25M at $18.25/share for 1.37M shares; BMS appoints member to Global Steering Committee.
Kura Oncology reports Phase 1b KOMET-001 data for ziftomenib in R/R AML; 600 mg shows 25% CR/CRh
Phase 1b at 600 mg (N=12): 25% CR/CRh rate, 33% composite CR (75% MRD-), 42% ORR.
KURA Oncology amends equity plan to increase shares by 1.46M and grants PSUs to executives
Board approved amendment to 2014 Equity Incentive Plan to increase shares by 1,459,800, subject to stockholder approval at 2023 Annual Meeting.
Kura Oncology Q2 net loss $34.8M; identifies ziftomenib Phase 2 dose, $450M cash runway through 2024
Net loss of $34.8M in Q2 2022 vs. $33.7M in Q2 2021; R&D expenses rose to $24.3M.
On January 1, 2025 (the “Dale Separation Date”), Stephen Dale, M.D. tendered his resignation from his position as the Chief Medical Officer of Kura Oncology, Inc. (the “Company”), effective as of January 2, 2025, in order to focus on recovery from personal health challenges.
On September 13, 2024, the Board of Directors (the “Board”) of Kura Oncology, Inc. (the “Company”), upon recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Michael J. Vasconcelles, M.D. as (i) a Class III director of the Company
On January 10, 2023, Kirsten Flowers notified Kura Oncology, Inc. (the “Company”) of her intention to resign from her position as the Company’s Chief Commercial Officer, effective as of January 27, 2023 (the “Separation Date”), in order to pursue other opportunities.
On January 26, 2022, Marc Grasso, M.D. notified Kura Oncology, Inc. (the “Company”) of his intention to resign from his positions as the Company’s Chief Financial Officer and Chief Business Officer, principal accounting officer and principal financial officer, effective as of February 4, 2022 (the “Separation Date”), in order to pursue opportunities closer to his family.
On January 31, 2022, the Board of Directors of the Company (the “Board”) appointed (i) Thomas Doyle, the Company’s Vice President, Finance, as the Company’s Senior Vice President, Finance and Accounting and as the Company’s principal accounting officer, and (ii) Troy E. Wilson, Ph.D., J.D., the Company’s President and Chief Executive Officer, as the Company’s principal financial officer, each effective as of February 7, 2022.
On January 31, 2022, the Board of Directors of the Company (the “Board”) appointed (i) Thomas Doyle, the Company’s Vice President, Finance, as the Company’s Senior Vice President, Finance and Accounting and as the Company’s principal accounting officer, and (ii) Troy E. Wilson, Ph.D., J.D., the Company’s President and Chief Executive Officer, as the Company’s principal financial officer, each effective as of February 7, 2022.
appointed Helen Collins, M.D. as a Class II director of the Company
Max materiality 0.90 · Median 0.65 · Most common event other_material